Covid- 19 and Myocardium

AUTHORS

Iman Razeghian-Jahromi ORCID 1 , Zahra Elyaspour ORCID 1 , Zahra Daneshvar ORCID 1 , Mohammad Javad Zibaeenezhad ORCID 1 , *

1 Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran

How to Cite: Razeghian-Jahromi I, Elyaspour Z, Daneshvar Z , Zibaeenezhad M J . Covid- 19 and Myocardium, Int Cardio Res J. 2020 ; 14(3):e107069.

ARTICLE INFORMATION

International Cardiovascular Research Journal: 14 (3); e107069
Published Online: September 01, 2020
Article Type: Review Article
Received: June 30, 2020
Accepted: August 01, 2020
READ FULL TEXT

Abstract

Context: The COVID-19 pandemic has involved several millions of people around the
world and has dragged thousands of individuals to death. Unfortunately, it seems to be
unstoppable for the near future. This review aimed to have a comprehensive appraisal
on the latest studies conducted on different aspects of myocardial injury related to
COVID-19.
Evidence Acquisition: The researchers searched for accredited international
investigations, whether original, review, letters, or commentaries or any other published
data, in Pubmed/Medline, Google Scholar, Web of Science, Wiley Online Library, and
Research Gate databases.
Results: Although the dominant manifestation of the disease was related to the
respiratory system, a growing body of evidence has suggested that the cardiovascular
system was also a target for SARS-CoV-2. In this regard, myocardium suffered injury
by possible direct and indirect mechanisms. Two patterns of myocardial injury were
seen particularly in critical cases of COVID-19; presentation with acute myocardial
injury and development of myocardial injury with escalation of the viral illness.
In the case of myocardial damage, a cascade of life-threatening adverse events will
deteriorate the functions of the cardiovascular system as well as other vital organs.
Cardiac biomarkers are helpful for early diagnosis of myocardial injury. Hypertension,
previous cardiovascular diseases, and diabetes have been considered to be the foremost
clinical risk factors in the setting of COVID-19. The jeopardy of arrhythmia, thrombotic
complications, acute myocardial infarction, and myocarditis are also anticipated in
patients with COVID-19. Thrombolytics have been found to contribute substantially to
life-saving treatment regimen.
Conclusions: Cardiovascular damage in terms of myocardial injury has been assigned a
considerable share in patients with COVID-19, which is of paramount importance due
to the elevation of the fatality rate. While there is no exclusive medication for this viral
uninvited guest, much attention should be paid to maintenance of cardiovascular health,
which plays a critical role in the battlefield with COVID-19.

© 0, Shiraz University of Medical Sciences.

Fulltext

The full-text is available in pdf.

References

  • 1.

    The references are available in pdf.

  • COMMENTS

    LEAVE A COMMENT HERE: